Skip to content

Analgesia in Knee Arthroscopic Surgery

Intra-articular Dexamethasone vs Intra-articular Dexamedetomidine

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02818985
Enrollment
60
Registered
2016-06-30
Start date
2016-06-30
Completion date
2017-02-28
Last updated
2017-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

Pain relief in knee Arthroscopic Surgery is essential for rapid recovery of function.

Detailed description

Intra-articular analgesia is useful in reducing patients' postoperative disability. It anticipates and prevents the onset of pain, and helps avoid the need for additional drugs. Usually it is possible to reach good analgesia in the immediate postoperative period by the administration of analgesic drugs. Recently, intra-articular administration of different anaesthetic substances with a local action (e.g. bupivacaine) has been introduced in clinical practice. The aim of the administration of these substances should not be the reduction of postoperative pain, but its prevention.

Interventions

DRUGDexamethasone

patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.

DRUGDexmedetomidine

patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.

DRUGSaline

patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for knee arthroscopy under spinal anaesthesia

Exclusion criteria

* Diabetes Mellitus * Contraindication to spinal anesthesia * Patient refusal

Design outcomes

Primary

MeasureTime frameDescription
pain free time48 hoursVAS

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026